Scientific article

Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid fever

Published inEuropean journal of clinical microbiology, vol. 4, no. 3, p. 295-298
Publication date1985

The efficacy of the live oral typhoid fever vaccine Ty 21a marketed in Switzerland in 1981 was investigated. Forty-seven Swiss travellers to Third World countries contracted typhoid fever in 1982 and 1983; 20 (43%) of these persons had been vaccinated with Ty 21a. The incidence of typhoid fever in vaccinees was 1.1 per 10,000 doses of Ty 21a vaccine sold, which was similar to the incidence of 0.9 per 10,000 doses for the ineffective killed Ty 2 vaccine. Comparison of the incidence of vaccination in patients with typhoid fever in 1983 and in healthy travellers to India revealed vaccination efficacy rates which were not significantly different from zero. It is suggested that Ty 21a vaccine in the form marketed in Switzerland in 1981-1983 is not sufficiently potent or heat-stable, so that the doses of viable bacteria ingested were too low.

  • Administration, Oral
  • Adult
  • Feces/microbiology
  • Female
  • Humans
  • Male
  • Salmonella typhi/growth & development/metabolism
  • Switzerland
  • Typhoid Fever/ prevention & control
  • Typhoid-Paratyphoid Vaccines/administration & dosage
  • Vaccination
  • Vaccines, Attenuated
Citation (ISO format)
HIRSCHEL, Bernard et al. Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid fever. In: European journal of clinical microbiology, 1985, vol. 4, n° 3, p. 295–298. doi: 10.1007/bf02013656
ISSN of the journal0722-2211

Technical informations

Creation07/12/2010 2:36:56 PM
First validation07/12/2010 2:36:56 PM
Update time03/14/2023 3:54:27 PM
Status update03/14/2023 3:54:27 PM
Last indexation01/15/2024 8:51:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack